These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35977240)

  • 21. Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims.
    Xu KY; Gertner AK; Greenfield SF; Williams AR; Grucza RA
    Addict Sci Clin Pract; 2024 Mar; 19(1):17. PubMed ID: 38493109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018.
    Andrews CM; Westlake MA; Abraham AJ; Grogan CM; Harris SJ; Jehan S
    Health Aff (Millwood); 2024 Jan; 43(1):55-63. PubMed ID: 38190595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pronounced State-Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019-2020).
    Dana SR; Nichols SD; McCall KL; Piper BJ
    J Stud Alcohol Drugs; 2024 Jan; 85(1):19-25. PubMed ID: 37650858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020.
    Strahan AE; Desai S; Zhang K; Guy GP
    JAMA Netw Open; 2023 Feb; 6(2):e2254590. PubMed ID: 36763363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
    Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
    JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.
    Griffin BA; Cabreros I; Saloner B; Gordon AJ; Kerber R; Stein BD
    Subst Abus; 2023 Jul; 44(3):136-145. PubMed ID: 37401501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.
    Andraka-Christou B; Simon KI; Bradford WD; Nguyen T
    Health Aff (Millwood); 2023 May; 42(5):658-664. PubMed ID: 37126752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.
    Knudsen HK; Hartman J; Walsh SL
    Drug Alcohol Depend; 2022 Mar; 232():109336. PubMed ID: 35123365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.
    Wen H; Hockenberry JM; Borders TF; Druss BG
    Med Care; 2017 Apr; 55(4):336-341. PubMed ID: 28296674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.
    Clark RE; Baxter JD; Barton BA; Aweh G; O'Connell E; Fisher WH
    Health Serv Res; 2014 Dec; 49(6):1964-79. PubMed ID: 25040021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs.
    Andrews CM; Abraham AJ; Grogan CM; Westlake MA; Pollack HA; Friedmann PD
    Am J Public Health; 2019 Mar; 109(3):434-436. PubMed ID: 30676789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program.
    Gordon AJ; Lo-Ciganic WH; Cochran G; Gellad WF; Cathers T; Kelley D; Donohue JM
    J Addict Med; 2015; 9(6):470-7. PubMed ID: 26517324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. National trends in buprenorphine prescribing before and during the COVID-19 pandemic.
    Ali MM; Creedon TB; Jacobus-Kantor L; Sherry TB
    J Subst Abuse Treat; 2023 Jan; 144():108923. PubMed ID: 36334383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in Buprenorphine to Treat Opioid Use Disorder in California, 2012 to 2018: Medicaid Outpaces the Rest of the State.
    Tseregounis IE; Gasper JJ; Henry SG
    J Addict Med; 2021 Sep-Oct 01; 15(5):425-428. PubMed ID: 33186262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of patterns of distribution of buprenorphine in the United States using ARCOS, Medicaid, and Medicare databases.
    Hsu ZS; Warnick JA; Harkins TR; Sylvester BE; Bharati NK; Eley LB; Nichols SD; McCall K; Piper BJ
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01115. PubMed ID: 37485957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
    Spence O; Reeves G; dosReis S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use.
    Auty SG; Shafer PR; Dusetzina SB; Griffith KN
    JAMA Health Forum; 2021 Aug; 2(8):e212285. PubMed ID: 35977199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022.
    Ross RK; Rudolph KE; Shover CL
    Addiction; 2024 Dec; 119(12):2211-2215. PubMed ID: 39149781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A bridge too far? Distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid.
    Saloner B; Landis RK; Jayakrishnan R; Stein BD; Barry CL
    Subst Abus; 2022; 43(1):682-690. PubMed ID: 35099362
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.